Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 8/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514974 | 0.85 | CHRNA7 (0.76) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL30932155 | 0.85 | CHRNA7 (0.76) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL30363169 | 0.85 | CHRNA7 (0.76) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL28765330 | 0.84 | CHRNA7 (0.70) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL30363191 | 0.84 | CHRNA7 (0.70) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL6406929 | 0.83 | MTNR1B (0.49) | CHRNA7DRD1DRD2 | |
| SCHEMBL21877880 | 0.82 | RAD52 (0.61) | CHRNA7RAD52DRD1DRD2HTR1A | |
| SCHEMBL5320509 | 0.80 | CHRNA7 (0.51) | CHRNA7RAD52 | |
| SCHEMBL6001623 | 0.80 | MTNR1B (0.70) | — | |
| SCHEMBL6406088 | 0.79 | MTNR1B (0.47) | CHRNA7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1603395-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080170-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | CBR3, L3MBTL3, BRS3 | CHRNA7 1146/4885RAD52 424/4885DRD1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.